Clene

Clene Net Debt/Equity

The Net Debt to Equity Ratio of Clene (CLNN) as of Nov 16, 2026 is -0.94. In the previous year, Net Debt to Equity Ratio was -0.98 — a change of -4.48% (higher).

Net Debt/Equity

-0.94

YoY

-4.48%

Last updated:

Net Debt to Equity Ratio of Clene is 2025 -0.94 . Net Debt to Equity Ratio of Clene was 2024 -0.98 . It decreases by -4.48% higher compared to the previous year.

The Clene Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
0.50 USD
Jan 1, 2019
-1.21 USD
Jan 1, 2020
-161.15 USD
Jan 1, 2021
-2.08 USD
Jan 1, 2022
2.63 USD
Jan 1, 2023
-0.21 USD
Jan 1, 2024
-0.98 USD
Jan 1, 2025
-0.94 USD
The Clene Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.94-4.48%
-0.98+362.65%
-0.21-108.07%
2.63-226.17%
-2.08-98.71%
-161.15+13,227.77%
-1.21-343.75%
0.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Net Debt to Equity Ratio of Clene is -0.94 in 2025.

Net Debt to Equity Ratio of Clene changed from -0.98 to -0.94, representing a -4.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Clene since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Clene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Clene

All Key Metrics — Clene